336 related articles for article (PubMed ID: 30891423)
1. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.
Yang H; Zhou X; Sun L; Mao Y
Front Oncol; 2019; 9():47. PubMed ID: 30891423
[No Abstract] [Full Text] [Related]
2. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
3. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
4. Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis.
Lin X; Lin K; Lin C; Liu T; Ba M; Tang Y; Wang J; Zhou L; Wang J; Xiao C
Int Immunopharmacol; 2021 Feb; 91():107280. PubMed ID: 33370681
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Wang Q; Liu F; Liu L
Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis.
Lin X; Lin K; Lin C; Wang J; Tang Y
Int Immunopharmacol; 2020 Nov; 88():106946. PubMed ID: 33182023
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis.
Zhou ZY; Liu SR; Xu LB; Liu C; Zhang R
J Clin Transl Hepatol; 2021 Dec; 9(6):889-897. PubMed ID: 34966652
[TBL] [Abstract][Full Text] [Related]
8. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
10. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis.
Hao C; Chen G; Zhao H; Li Y; Chen J; Zhang H; Li S; Zhao Y; Chen F; Li W; Jiang WG
Front Oncol; 2020; 10():1015. PubMed ID: 32670884
[No Abstract] [Full Text] [Related]
13. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
15. Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis.
Zhou X; Sun L; Jing D; Xu G; Zhang J; Lin L; Zhao J; Yao Z; Lin H
Front Physiol; 2018; 9():452. PubMed ID: 29765332
[No Abstract] [Full Text] [Related]
16. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z
Front Oncol; 2020; 10():749. PubMed ID: 32582532
[No Abstract] [Full Text] [Related]
18. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Lu L; Li Y; Luo R; Xu J; Feng J; Wang M
Front Oncol; 2020; 10():632. PubMed ID: 32426281
[No Abstract] [Full Text] [Related]
19. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H; Zhang H; Jiang Y
Front Oncol; 2020; 10():1079. PubMed ID: 32670887
[No Abstract] [Full Text] [Related]
[Next] [New Search]